


# Pharma 2020 Series Executive Summary

## Previous publications in this series include:



Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike.

This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and providers, can address the changing needs of society more effectively.

Published in February 2009, this paper discusses the key forces reshaping the pharmaceutical marketplace, including the growing power of healthcare payers, providers and patients, and the changes required to create a marketing and sales model that is fit for the 21st century. These changes will enable the industry to market and sell its products more cost-effectively, to create new opportunities and to generate greater customer loyalty across the healthcare spectrum.

Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma's fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry.

All these publications are available to download at:  
[www.pwc.com/pharma2020](http://www.pwc.com/pharma2020)

Pharma's traditional strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for many years, but its R&D productivity has now plummeted and the environment in which it operates is changing dramatically. We believe that seven major trends are reshaping the marketplace:

- The burden of chronic disease is soaring – placing even greater pressure on already stretched healthcare budgets
- Healthcare policy-makers and payers are increasingly mandating what doctors can prescribe
- A growing number of healthcare payers are measuring the pharmacoeconomic performance of different medicines, and widespread use of electronic medical records will give them the data they need to insist on outcomes-based pricing
- The boundaries between different forms of healthcare are blurring, as clinical advances render previously fatal diseases chronic and the self-medication sector expands

- Demand for medicines is growing more rapidly in the emerging economies than the industrialised economies, a pattern that will continue for the next decade
- Governments everywhere are beginning to focus on prevention rather than treatment, although they have not yet invested very much in pre-emptive measures; and
- The regulators are becoming more cautious about approving truly innovative medicines.

These trends will compound the challenges Pharma already faces, but they will also provide some major opportunities. So what must the industry do to capitalise on them? We think that it will have to improve its understanding of disease, reduce its R&D costs significantly and spread its bets to improve its productivity. It will also have to tap the potential of the emerging economies and switch from selling medicines to managing outcomes. However, few, if any, companies will be able to perform these activities alone.

The global market for medicines is growing but the industry must transform to capitalise opportunities

## The virtualisation of R&D

Let's begin with R&D. If Pharma is to develop safe, efficacious new medicines more economically, it will have to learn much more about how the human body functions at the molecular level and the pathophysiological changes disease causes. Only then will it be able to develop a better understanding of how to modify or reverse these changes. This is a huge task – but one that several emerging technologies can help to facilitate.

Semantic technologies will, for example, make it much easier to identify the links between a particular disease and the biological pathways it affects, or the links between a particular molecule and its impact on the human body. Similarly, computer-aided molecule design will give researchers a much better starting point in the search for potent molecules.


Various academic institutes and bioinformatics firms are also building computer models of different organs and cells, with the ultimate aim of creating a “virtual man”. Developing such a model will require a massive

collaborative effort far exceeding that needed to complete the Human Genome Project. Nevertheless, predictive biosimulation is already playing a growing role in the R&D process and we anticipate that, by 2020, virtual cells, organs and animals will be widely employed in pharmaceutical research (see **Figure 1**).

Of course, even the most robustly modelled molecules will still have to be tested in real human beings. However, here too, we expect some dramatic changes. When biomarkers for diagnosing and treating patients more accurately are more widely available, for example, the industry will be able to stratify patients with different but related conditions and test new medicines only in patients who suffer from a specific disease subtype. That will enable it to reduce the number and size of the clinical studies required to prove efficacy. Semantic technologies will also play a major role in improving the development process, while pervasive monitoring will enable Pharma to track patients on a real-time basis wherever they are.

## Companies will use virtual R&D to increase innovation and reduce commercial deficit

Figure 1: What the research process might look like in 2020



Source: PricewaterhouseCoopers

We think that these scientific and technological advances will ultimately render the current model of development, with its four distinct phases of clinical testing, defunct. A company will start by administering a treatment to a single patient who has been screened to ensure that he or she has the right medical profile. Once there is evidence that the treatment does not cause any immediate adverse events, it will be sequentially administered to other patients – from as few as 20 to as many as 100. The data they generate will be compared to data from the modelling that preceded the study and subjected to techniques like Bayesian analysis to adapt the course of the study, but the study itself will be conducted in a single, continuous phase (see **Figure 2**).

The development process will also become much more iterative, with data on a molecule for one disease subtype getting fed back into the development of new molecules for other disease subtypes in the same cluster of related diseases. And the current system of conducting trials at multiple sites will be replaced with a system based


on independently managed clinical supercentres.

The regulatory process will change equally substantially over the next decade. First, there will be a common regulatory regime for all healthcare products and services, rather than separate regimes for pharmaceuticals, medical devices, diagnostics and the like. Indeed, there may even be a single global system, administered by national or federal agencies responsible for ensuring that new treatments meet the needs of patients within their respective domains, although we think the latter is less likely.

Second, the current “all-or-nothing” approach to the approval of new medicines will be replaced by a cumulative process, based on the gradual accretion of data. In other words, all newly approved therapies will receive “live licences” conditional on further in-life testing to substantiate their safety and efficacy in larger populations, different populations or the treatment of other conditions.

However, if they are to capitalise on the new technologies now emerging and the

**Figure 2: What the development process might look like in 2020**



Source: PricewaterhouseCoopers

creation of a nimbler, more collaborative regulatory regime, many companies will have to make significant organisational and behavioural changes. They will, for example, have to decide whether they want to focus on mass-market medicines or speciality therapies, and whether they want to outsource most of their research or keep it in-house. Those that regard R&D as an integral part of their activities may also need to review the way they manage their R&D and remunerate their scientific staff.

## A new approach to marketing and sales

The industry's marketing and sales model will likewise have to undergo major alterations, as pay-for-performance becomes the norm in many countries and the opportunities for generating value from pure product offerings diminish. Many companies will have to analyse their own value chains to identify opportunities for working more closely with healthcare payers and providers. They will, for


instance, have to consult payers, providers and patients when deciding which compounds to progress through their pipelines. Some companies now look at whether the products they are developing are more effective than other existing therapies, but very few focus on understanding the payer's perspective. We believe that all companies should extend the concept of "de-risking" from the clinical to the commercial sphere to ensure that they are making medicines the market really wants to buy (see **Figure 3**).

Similarly, many companies will have to supplement the therapies they develop with a wide range of health management services. Most treatments perform much better in clinical trials than they do in everyday life. So, any pharmaceutical company that wants to command premium prices for its therapies will have to provide a range of products and services from which patients can choose all but the core prescription.

This route has several significant advantages. It will enable companies

Smaller, refocused sales force will enable pharma companies to create greater value for patients

**Figure 3: Pharma needs to use a price de-risking strategy in early development**



Source: PricewaterhouseCoopers

to generate new sources of revenue, differentiate their offerings more effectively and protect the value of the medicines they make. But it will also entail the formation of numerous alliances with local service providers and even rival manufacturers; the development of a secure, interoperable technological infrastructure; the management of new intellectual rights issues; the creation of much stronger brands; and the redefinition of the industry's role. Instead of trying to stimulate prescription sales, its task will be to help patients manage the disease lifecycle.

The shift to performance-based pricing will dictate other changes, too, including the need for a more flexible approach to pricing. The introduction of live licences and increasing importance of the emerging markets will reinforce this trend. Any company that launches a new healthcare package will have to negotiate price rises in line with the extension of the terms on which that package can be marketed. And if it wants to establish a stronger footing in the emerging world, it will have to use differential pricing – both within and

between countries.

Lastly, the industry leaders will have to develop comprehensive strategies for marketing and selling specialist healthcare packages, a process that will require the development of new skills and routes to market; and they will have to revolutionise their marketing and sales functions. By 2020, the role of the traditional sales representative will be largely obsolete. Conversely, the industry will have much greater need of people with the expertise to build brands; manage a network of external alliances; negotiate with governments and health insurers; liaise with secondary-care specialists; and communicate with patients.

## **The need for new business models**

The changes we have outlined above will all necessitate the development of multinational, multi-disciplinary networks drawing on a much wider range of skills than Pharma alone can

**Challenging times  
require bold moves  
if pharma companies  
are to survive  
immediate storm**

provide. Most companies will therefore need to adopt new business models.

We believe that two principal models – federated and fully diversified – will emerge. The federated model comprises a network of separate organisations linked by a shared purpose and infrastructure. The fully diversified model comprises a network of entities owned by a single parent company. We have also identified two variants of the federated model. In the virtual version, a company outsources most or all of its activities; in the venture version, it manages a portfolio of investments (see **Figure 4**).


These models are not mutually exclusive. A fully diversified company might choose to use a federated model for certain aspects of its business, and vice versa. But we think that the federated model will ultimately dominate, primarily because it is quicker and more economic to implement.

The transition will not be easy, because collaborative business models are

far more complex than the integrated model that has previously prevailed. Disrupting the existing order can also have a major impact on a company’s short-term performance. We anticipate that many companies which choose the federated model will therefore adopt a progressive approach. They will start with opportunistic alliances; use the most successful alliances as building blocks to create more strategic, longer-lasting coalitions; and, finally, use the most successful coalitions to create a fully federated network of long-term partners.

However, the prospects for any pharmaceutical company that can make the switch are very promising. To date, Pharma has focused on the profits it can earn from the estimated 10-15% of the health budget that goes on medicines. Yet there are many opportunities to generate revenues by improving the way in which the remaining 85-90% is spent. It is these opportunities the industry will need to address in the brave new world of 2020.

**Figure 4: The different business models**



Source: PricewaterhouseCoopers

# Territory contacts

## Argentina

Diego Niebuhr  
[54] 11 4850 4705

## Australia

John Canning  
[61] 2 826 66410

## Belgium

Thierry Vanwelkenhuyzen  
[32] 2 710 7422

## Brazil (SOACAT)

Luis Madasi  
[55] 11 3674 1520

## Canada

Gord Jans  
[1] 905 897 4527

## China

Beatrijs Van Liedekerke  
[86] 10 6533 7223

## Czech Republic

Radmila Fortova  
[420] 2 5115 2521

## Denmark

Torben TOJ Jensen  
[45] 3 945 9243

Erik Todbjerg

[45] 3 945 9433

## Finland

Janne Rajalahti  
[358] 3 3138 8016

Johan Kronberg

[358] 9 2280 1253

## France

Jacques Denizeau  
[33] 1 56 57 10 55

## Germany

Volker Booten  
[49] 89 5790 6347

## India

Sharat Bansal  
[91] 22 6669 1538

## Ireland

John M Kelly  
[353] 1 792 6307

Enda McDonagh

[353] 1 792 8728

## Israel

Assaf Shemer  
[972] 3 795 4681

## Italy

Massimo Dal Lago  
[39] 045 8002561

## Japan

Kenichiro Abe  
[81] 80 3158 5929

## Luxembourg

Laurent Probst  
[352] 0 494 848 2522

## Mexico

Ruben Guerra  
[52] 55 5263 6051

## Netherlands

Arwin van der Linden  
[31] 20 5684712

## Poland

Mariusz Ignatowicz  
[48] 22 523 4795

## Portugal

Ana Lopes  
[351] 213 599 159

## Russia

Alina Lavrentieva  
[7] 495 967 6250

## Singapore

Abhijit Ghosh  
[65] 6236 3888

## South Africa

Denis von Hoesslin  
[27] 117 974 285

## Spain

Rafael Rodríguez Alonso  
[34] 91 568 4287

## Sweden

Liselott Stenudd  
[46] 8 555 33 405

## Switzerland

Clive Bellingham  
[41] 58 792 2822

Peter Kartscher

[41] 58 792 5630

Markus Prinzen

[41] 58 792 5310

## Turkey

Ediz Günsel  
[90] 212 326 6060

## United Kingdom

Andy Kemp  
[44] 20 7804 4408

## About PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group

PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group ([www.pwc.com/pharma](http://www.pwc.com/pharma)) provides clients with audit, tax and advisory services. The firm has extensive experience in delivering solutions on a wide range of strategic, financial and operational issues. The Pharmaceutical and Life Sciences Industry Group is part of PricewaterhouseCoopers' larger initiative for the health-related industries that brings together expertise and allows collaboration across all sectors in the health continuum.

### PwC contacts:

#### Simon Friend

Partner, Global Pharmaceutical and Life Sciences  
Industry Leader  
[simon.d.friend@uk.pwc.com](mailto:simon.d.friend@uk.pwc.com)  
[44] 20 7213 4875

#### Attila Karacsony

Director, Pharmaceutical and Life Sciences Marketing  
[attila.karacsony@us.pwc.com](mailto:attila.karacsony@us.pwc.com)  
[1] 973 236 5640

#### Dr. Steve Arlington

Partner, Global Pharmaceutical and Life Sciences  
Industry Leader  
[steve.arlington@uk.pwc.com](mailto:steve.arlington@uk.pwc.com)  
[44] 20 7804 3997

#### Marina Bello Valcarce

Global Pharma & Life Sciences Marketing and  
Knowledge Management  
[marina.bello.valcarce@uk.pwc.com](mailto:marina.bello.valcarce@uk.pwc.com)  
[44] 20 7212 8642

#### Anthony Farino

Partner, US Advisory Pharmaceutical and Life Sciences  
Advisory Services Leader  
[anthony.l.farino@us.pwc.com](mailto:anthony.l.farino@us.pwc.com)  
[1] 312 298 2631

[pwc.com/pharma](http://pwc.com/pharma)

This publication has been prepared for general guidance on matters of interest only, and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, PricewaterhouseCoopers does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.

© 2009 PricewaterhouseCoopers. All rights reserved. 'PricewaterhouseCoopers' refers to the network of member firms of PricewaterhouseCoopers International Limited, each of which is a separate and independent legal entity.